[Endothelin receptor antagonist, phosphodiesterase inhibitor, thromboxane inhibitor].
According to the advanced comprehension of pathophysiology of primary pulmonary hypertension (PPH), a therapeutical approach to PPH has changed recently. One of the breakthrough to the treatment of PPH is application of prostacyclin. It has been revealed that intravenous administration of prostacyclin has improved the prognosis and patient's quality of life. Another development of endothelin receptor antagonists and phosphodiesterase inhibitors have provided a novel pulmonary-specific effect. An endothelin receptor antagonist has a great inhibitory effect against pulmonary vasculature remodeling. In this regard, this regard, this receptor antagonist has superior effect to other medicines. Furthermore, a phosphodiesterase inhibitor shows a great decreasing effect on pulmonary hypertension with less effect on systemic blood pressure. These drugs will provide a great potential to the treatment of pulmonary hypertension.
Kakinuma
Y
Y
Cardiovascular Division, Department of Internal Medicine, Institute of Clinical Medicine, University of Tsukuba.
Miyauchi
T
T
D000818:Animals; D065128:Endothelin Receptor Antagonists; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008689:Methacrylates / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use; D011688:Purinones / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use
C091517:E 4021; D065128:Endothelin Receptor Antagonists; D004791:Enzyme Inhibitors; D008689:Methacrylates; D010726:Phosphodiesterase Inhibitors; D010880:Piperidines; D011688:Purinones; D011799:Quinazolines; C011145:zaprinast; C034364:ozagrel